PMEDF
Qscreen Ai Inc.·Healthcare
0.03
11.111%(+0.00)
Close PriceLast Updated: — ET
52W L: $0.0152W H: $0.07
PMEDF NEWS
newsfilecorp.com
May 19
QScreen AI Appoints Former Pentagon Joint Artificial Intelligence Center Director Lt. Gen. Michael S.
Former US Department of Defense AI leader joins QScreen AI after reviewing the platform in person to support institutional commercialization efforts across North America Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, today announces the appointment of Lieutenant General Michael S. Groen (Ret.
newsfilecorp.com
May 6
QScreen AI Integrates Passive Voice Analysis into Multi-Signal Screening Platform - System Now Reads Physiological, Acoustic, and Behavioral Signals Simultaneously in Real Time
Individual voice baseline established on first encounter, deviation measured on every return visit; no additional hardware required; platform now fully integrated across all three signal modalities Toronto, Ontario--(Newsfile Corp. - May 6, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen"), today announced the full integration of a novel voice analysis engine into its multi-signal screening platform, expanding the system from camera and structured clinical intake into a three-modality real-time screening solution. QScreen now assesses physiological, acoustic and behavioral indicators simultaneously during the same intake workflow using existing microphones already present on standard assessment devices.
newsfilecorp.com
May 4
QScreen AI Reports Internal Validation Results for Correctional Intake Platform: 100% Sensitivity on Suicide Risk and Withdrawal Detection Across 65 Calibrated Clinical Scenarios
Nine instruments validated against published standards including Columbia C-SSRS, CIWA-Ar, and COWS; paper-only workflow showed materially lower detection rates across the same scenarios; 60-day live pilot structured and ready Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening today reports internal validation results for its correctional intake platform across 65 calibrated clinical scenarios tested against published instrument thresholds. By digitizing the high-liability blind spots of correctional intake, QAI transforms a universal institutional risk into a scalable SaaS revenue model with zero-hardware deployment friction.
newsfilecorp.com
Apr 29
QScreen AI Appoints Former Union Pacific Vice President as Strategic Advisor to Drive Expansion into North American Rail and Transportation Markets
Veteran rail executive with 25 years of senior commercial relationships across North America's Class I railroads joins a platform that enables real-time identification of probable drug use from a camera without requiring blood, breath, or urine testing. Toronto, Ontario--(Newsfile Corp. - April 29, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening, today announces the appointment of José Humberto "Beto" Vargas García as Strategic Advisor.
newsfilecorp.com
Apr 27
QScreen AI Completes Platform That Identifies Probable Drug a Person Has Consumed in Real Time from a Camera Alone - Targets Correctional Facilities Facing Coroner Scrutiny over Withdrawal Deaths
Patent-protected QAI Platform identifies the probable drug class - alcohol, opioids, benzodiazepines, stimulants, or cannabis from physiological camera data and simultaneously administers CIWA-Ar, COWS, C-SSRS and 10 further validated clinical instruments in under seven minutes with no hardware and no IT project; former Director of Pentagon Joint Artificial Intelligence Center advancing commercial engagement across US correctional facilities and national defense installations; Canadian correctional health outreach underway Toronto, Ontario--(Newsfile Corp. - April 27, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening, today provides a commercialization update. The Company has completed development of its QAI physiological AI clinical platform and has commenced outreach to prospective facility partners across correctional health and national defense verticals in Canada and the United States.
